The malignant brain tumor Glioblastoma (GBM) is a tragic illness for patients and families due to poor patientprognosis, with only 9.8% of patients surviving past 5 years. Only modest gains in survival have been madedespite decades of research, therefore, a better understanding of the basic biology of this disease is needed toimprove patient outcomes. Hypoxia is characteristic of GBM and many other tumors, and is increased by theanti-angiogenic agent bevacizumab, which is commonly used for recurrent GBM tumors.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.
Latest Projects
The University of Texas at San Antonio
The University of Texas at San Antonio
Southwest Research Institute
Southwest Research Institute
The University of Texas at San Antonio
The University of Texas at San Antonio